Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet's Uveitis

Turk J Ophthalmol. 2022 Apr 28;52(2):142-146. doi: 10.4274/tjo.galenos.2022.96461.

Abstract

Corticosteroid-induced central serous chorioretinopathy (CSCR) has been reported to develop in many intraocular inflammatory diseases and usually resolves spontaneously after discontinuation of corticosteroids. Patients without any improvement may require alternative therapies. In this case report, we present the case of a 35-year-old man with Behçet's disease who had complaints of decreased vision due to CSCR in his left eye while using systemic corticosteroids along with cyclosporine and azathioprine. Half-fluence photodynamic therapy (PDT) was performed because the CSCR did not regress despite discontinuation of systemic corticosteroids. After treatment, his visual acuity increased with complete resolution of the subfoveal fluid. Half-fluence PDT seems to be an effective and safe treatment for patients who develop acute CSCR while under systemic or local corticosteroid therapy for intraocular inflammatory diseases such as Behçet's uveitis and do not improve despite steroid discontinuation.

Keywords: Behçet’s disease; central serous chorioretinopathy; photodynamic therapy; steroid; uveitis.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Behcet Syndrome* / complications
  • Behcet Syndrome* / diagnosis
  • Behcet Syndrome* / drug therapy
  • Central Serous Chorioretinopathy* / chemically induced
  • Central Serous Chorioretinopathy* / diagnosis
  • Central Serous Chorioretinopathy* / drug therapy
  • Fluorescein Angiography
  • Humans
  • Male
  • Photochemotherapy* / adverse effects
  • Photosensitizing Agents / adverse effects
  • Tomography, Optical Coherence
  • Uveitis* / drug therapy
  • Verteporfin / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Photosensitizing Agents
  • Verteporfin